Skip to main content

Table 4 Association between SNPs and patients’ adverse events during NAC

From: Genetic polymorphisms of GGT1 gene (rs8135987, rs5751901 and rs2017869) are associated with neoadjuvant chemotherapy efficacy and toxicities in breast cancer patients

Toxic reactions

SNP

Genotypes

Toxicity grade

OR(95%CI)

pA

Neutropenia

  

Grade < 2

Grade ≥ 2

  

rs8135987 (T > C)

TT

9(42.9)

38(44.7)

  
 

TC

7(33.3)

39(45.9)

1.66(0.52–5.24)

0.391

 

CC

5(23.8)

8(9.4)

0.47(0.11–2.04)

0.314

 

TT vs. TC + CC

  

1.15(0.42–3.18)

0.790

 

TT + TC vs. CC

  

0.38(0.09–1.54)

0.175

 

TT + CC vs. TC

  

1.96(0.66–5.83)

0.227

rs5751901 (T > C)

TT

6(28.6)

36(42.4)

  
 

TC

8(38.1)

38(44.7)

0.70(0.25–2.96)

0.824

 

CC

7(33.3)

11(12.9)

0.26(0.07–1.01)

0.052

 

TT vs. TC + CC

  

0.56(0.19–1.67)

0.300

 

TT + TC vs. CC

  

0.29(0.09–0.96)

0.036

 

TT + CC vs. TC

  

1.43(0.49–4.12)

0.504

rs2017869 (G > C)

GG

7(33.3)

37(43.5)

  
 

GC

7(33.3)

38(44.7)

1.23(0.36–4.20)

0.740

 

CC

7(33.3)

10(11.8)

0.28(0.08–1.04)

0.059

 

GG vs. GC + CC

  

0.70(0.24–2.03)

0.514

 

GG + GC vs. CC

  

0.39(0.08–0.84)

0.025

 

GG + CC vs. GC

  

1.90(0.63–5.72)

0.251

Leukopenia

  

Grade < 2

Grade ≥ 2

  

rs8135987 (T > C)

TT

8(33.3)

39(47.6)

  
 

TC

9(37.5)

37(45.1)

0.85(0.36–4.20)

0.765

 

CC

7(29.2)

6(7.3)

0.16(0.05–0.68)

0.014

 

TT vs. TC + CC

  

0.54(0.19–1.47)

0.229

 

TT + TC vs. CC

  

0.17(0.04–0.67)

0.012

 

TT + CC vs. TC

  

1.30(0.48–3.52)

0.602

rs5751901 (T > C)

TT

8(33.3)

34(41.5)

  
 

TC

8(33.3)

38(46.3)

0.99(0.31–3.13)

0.998

 

CC

8(33.3)

10(12.2)

0.27(0.07–0.96)

0.045

 

TT vs. TC + CC

  

0.63(0.23–1.71)

0.363

 

TT + TC vs. CC

  

0.27(0.09–0.84)

0.024

 

TT + CC vs. TC

  

1.59(0.58–4.34)

0.370

rs2017869 (G > C)

GG

9(37.5)

35(42.7)

  
 

GC

7(29.2)

38(46.3)

1.29 (0.40–4.13)

0.663

 

CC

8(33.3)

9(11.0)

0.27 (0.08–0.97)

0.045

 

GG vs. GC + CC

  

0.71(0.27–1.95)

0.523

 

GG + GC vs. CC

  

0.24(0.08–0.78)

0.017

 

GG + CC vs. GC

  

1.97(0.69–5.64)

0.204

Peripheral neuropathy

  

Grade < 2

Grade ≥ 2

  

rs8135987 (T > C)

TT

26(39.4)

21(52.5)

  
 

TC

34(51.5)

12(30.0)

0.43(0.17–1.09)

0.078

 

CC

6(9.1)

7(17.5)

1.70(0.41–7.07)

0.459

 

TT vs. TC + CC

  

0.60(0.26–1.40)

0.236

 

TT + TC vs. CC

  

2.42(0.61–9.59)

0.206

 

TT + CC vs. TC

  

0.39(0.15–0.96)

0.042

rs5751901 (T > C)

TT

27(40.9)

15(37.5)

  
 

TC

30(45.5)

16(40.0)

1.95(0.59–6.45)

0.270

 

CC

9(13.6)

9(22.5)

0.96(0.37–2.47)

0.928

 

TT vs. TC + CC

  

1.19 (0.50–2.85)

0.688

 

TT + TC vs. CC

  

2.00(0.67–5.96)

0.213

 

TT + CC vs. TC

  

0.77(0.32–1.83)

0.561

rs2017869 (G > C)

GG

28(42.4)

16(40.0)

  
 

GC

29(43.9)

16(40.0)

0.96(0.37–2.49)

0.939

 

CC

9(13.6)

8(20.0)

0.69(0.50–5.65)

0.393

 

GG vs. GC + CC

  

1.15(0.48–2.73)

0.757

 

GG + GC vs. CC

  

1.72(0.56–5.25)

0.340

 

GG + CC vs. GC

  

0.83(0.34–1.98)

0.668

AST increased

  

Grade < 1

Grade ≥ 1

  

rs8135987 (T > C)

TT

29(51.8)

18(36.0)

  
 

TC

22(29.3)

24(48.0)

1.50(0.60–3.66)

0.386

 

CC

5(8.9)

8(16.0)

5.40(1.24–23.4)

0.024

 

TT vs. TC + CC

  

1.94(0.84–4.50)

0.122

 

TT + TC vs. CC

  

4.50(1.11–18.27)

0.035

 

TT + CC vs. TC

  

1.09(0.46–2.53)

0.844

rs5751901 (T > C)

TT

25(44.6)

17(34.0)

  
 

TC

22(39.3)

24(48.0)

1.67(0.50–5.47)

0.401

 

CC

9(16.1)

9(18.0)

1.28(0.51–3.20)

0.591

 

TT vs. TC + CC

  

1.39(0.59–3.22)

0.448

 

TT + TC vs. CC

  

1.47(0.49–4.41)

0.493

 

TT + CC vs. TC

  

1.10(0.48–2.55)

0.818

rs2017869 (G > C)

GG

26(49.1)

18(36.0)

  
 

GC

22(39.3)

23(46.0)

1.13(0.45–2.86)

0.784

 

CC

8(14.3)

9(18.0)

1.96(0.58–6.60)

0.279

 

GG vs. GC + CC

  

1.34(.057–3.10)

0.500

 

GG + GC vs. CC

  

1.84(4.58–5.77)

0.293

 

GG + CC vs. GC

  

0.95(0.40–2.23)

0.904

  1. AST Aspartate transaminase
  2. AP values were analyzed with adjustment for age, BMI, menses, ER, PR, if accepted Herceptin or not